Skip to main content

What the FDA labels say about taking them together

Acalabrutinib and ranitidine

Acalabrutinib's FDA label (Calquence) of February 19, 2026 names ranitidine in its drug interactions section; the ranitidine label PlainMeds reads does not name acalabrutinib.

Check it at the source: the acalabrutinib FDA label on DailyMed (effective February 19, 2026, AstraZeneca Pharmaceuticals LP); the ranitidine FDA label on DailyMed (effective May 1, 2026, Amneal Pharmaceuticals of New York LLC).

What does the acalabrutinib label say about ranitidine?

Calquence label (AstraZeneca Pharmaceuticals LP, February 19, 2026), drug interactions

If treatment with a gastric acid reducing agent is required, consider using a H2‑receptor antagonist (e.g., ranitidine or famotidine) or an antacid (e.g., calcium carbonate).

Source: FDA drug label (Calquence, NDA210259), AstraZeneca Pharmaceuticals LP, effective February 19, 2026 (SPL set dd4835ef-e1bc-4997-a399-1ffa2556fbfe), via openFDA

Source: FDA drug label (CALQUENCE), AstraZeneca Pharmaceuticals LP, effective February 19, 2026 (SPL set b1409184-3267-4d8c-8f17-4e01f69828b1), via openFDA; the full label on DailyMed

What does the ranitidine label say about acalabrutinib?

Ranitidine's label (effective May 1, 2026) does not name acalabrutinib in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Ranitidine), Amneal Pharmaceuticals of New York LLC, effective May 1, 2026 (SPL set b38a3332-5c54-453f-aeb7-070f830955c2), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Acalabrutinib generic labelers
8Ranitidine generic labelers
AcalabrutinibRanitidine
Labeled forLeukemia, lymphoma and myelomaAcid reflux and ulcers
Boxed warningNoNo
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?